T2 Mapping (relaxometry)

Quibim

Quibim has developed this suite to automatically obtain the T2 mapping of tumors and depict changes and abnormalities with AI segmentation. The analysis of T2 mapping provides imaging biomarkers for the assessment and monitoring of solid tumors, such as prostate cancer, rectal cancer and liver cancer, among others.

Product specifications

Information source: Vendor
Last updated: Feb. 11, 2022

General
Product name	T2 Mapping (relaxometry)
Company	Quibim
Subspeciality	Abdomen, Breast
Modality	MR
Disease targeted	Solid tumors, Prostate cancer, Rectal cancer, Endometrial cancer, Liver cancer
Key-features	T2 values, T2 Histogram
Suggested use	During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand) (Need to draw ROI)
Data characteristics
Population	Assessment and monitoring of solid tumors and cartilage changes
Input	MRI T2 Multi-echo
Input format
Output	One-page structured report: ROI, T2 map, T2 histogram, T2 fitting, statistics summary
Output format
Technology
Integration	Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment	Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis	Automatically after drawing ROI
Processing time	1 - 10 minutes
Certification
CE	Certified, Class IIa , MDD
FDA	No or not yet
Market presence
On market since	01-2019
Distribution channels	Alma HEALTH PLATFORM
Countries present (clinical, non-research use)	2
Paying clinical customers (institutes)	5+
Research/test users (institutes)
Pricing
Pricing model	License
Based on	Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers	Crema MD et al. Articular cartilage in the knee: current MR imaging techniques and applications in clinical practice and research. RadioGraphics 2011;31:37-61. Sanz-Requena R et al. Modification of longitudinal relaxation time (T1) as a biomarker of patellar cartilage degeneration. Radiologia 2010;52:221-227. Sanz R et al. MR pharmacokinetic modeling of the patellar cartilage differentiates normal from pathological conditions. J Magn Reson Imaging 2008;27:171-177.